
Opinion|Videos|August 8, 2024
Esketamine for TRD: MOA, Application, and Adverse Events
Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial
2
GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D
3
ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin
4
VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes
5































































